134 related articles for article (PubMed ID: 8113839)
1. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome.
Foss FM; Koc Y; Stetler-Stevenson MA; Nguyen DT; O'Brien MC; Turner R; Sausville EA
J Clin Oncol; 1994 Feb; 12(2):326-35. PubMed ID: 8113839
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-7 is a growth factor for Sézary lymphoma cells.
Dalloul A; Laroche L; Bagot M; Mossalayi MD; Fourcade C; Thacker DJ; Hogge DE; Merle-Béral H; Debré P; Schmitt C
J Clin Invest; 1992 Sep; 90(3):1054-60. PubMed ID: 1381718
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells.
Döbbeling U; Dummer R; Laine E; Potoczna N; Qin JZ; Burg G
Blood; 1998 Jul; 92(1):252-8. PubMed ID: 9639524
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
5. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 production and interleukin 2 receptor expression by human immature leukemic T cells.
Sahraoui Y; Allouche M; Ammar A; Spanakis E; Clemenceau C; Jasmin C; Perraki M; Varela-Millot C; Georgoulias V
Leukemia; 1992 Oct; 6(10):1025-35. PubMed ID: 1405755
[TBL] [Abstract][Full Text] [Related]
7. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.
van der Fits L; Out-Luiting JJ; van Leeuwen MA; Samsom JN; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Feb; 132(2):440-7. PubMed ID: 21938013
[TBL] [Abstract][Full Text] [Related]
8. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
9. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
10. CD7-positive Sézary syndrome with a Th1 cytokine profile.
Yagi H; Tokura Y; Furukawa F; Takigawa M
J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):368-74. PubMed ID: 8655729
[TBL] [Abstract][Full Text] [Related]
11. mu-Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome.
Bénard A; Cavaillès P; Boué J; Chapey E; Bayry J; Blanpied C; Meyer N; Lamant L; Kaveri SV; Brousset P; Dietrich G
J Invest Dermatol; 2010 May; 130(5):1337-44. PubMed ID: 20107485
[TBL] [Abstract][Full Text] [Related]
12. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-7 receptor expression in cutaneous T-cell lymphomas.
Bagot M; Charue D; Boulland ML; Gaulard P; Revuz J; Schmitt C; Wechsler J
Br J Dermatol; 1996 Oct; 135(4):572-5. PubMed ID: 8915148
[TBL] [Abstract][Full Text] [Related]
14. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
15. Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4.
Showe LC; Fox FE; Williams D; Au K; Niu Z; Rook AH
J Immunol; 1999 Oct; 163(7):4073-9. PubMed ID: 10491012
[TBL] [Abstract][Full Text] [Related]
16. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-16 as a marker of Sézary syndrome onset and stage.
Richmond J; Tuzova M; Parks A; Adams N; Martin E; Tawa M; Morrison L; Chaney K; Kupper TS; Curiel-Lewandrowski C; Cruikshank W
J Clin Immunol; 2011 Feb; 31(1):39-50. PubMed ID: 20878214
[TBL] [Abstract][Full Text] [Related]
18. Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12.
Suchin KR; Cassin M; Gottleib SL; Sood S; Cucchiara AJ; Vonderheid EC; Rook AH
J Am Acad Dermatol; 2001 Jan; 44(1):28-32. PubMed ID: 11148473
[TBL] [Abstract][Full Text] [Related]
19. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
20. Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome.
Abrams JT; Ghosh SK; DeFreitas E
Cancer Res; 1993 Nov; 53(22):5501-6. PubMed ID: 8221690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]